ABOUT ICAGEN

Our mission at Icagen is to apply our expertise in ion channel technologies towards the discovery, development and commercialization of innovative drugs in diverse therapeutic areas with significant unmet medical need.

Company Overview
Icagen is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that target ion channels. Learn more

Product Pipeline
Icagen is developing first-in-class drug candidates targeting specific ion channels across a broad range of therapeutic areas.  We currently have a compound in clinical development, ICA-17043, for which we are conducting a Phase III clinical trial for the treatment of sickle cell disease.  In addition, we have several compounds in preclinical

development and many more in our discovery pipeline.
Learn more